WASHINGTON, Oct. 11, 2016
WASHINGTON, Oct. 11, 2016 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox P.L.L.C. is proud to announce the publication, by Thomson Reuters, of U.S. Biotechnology Patent Law. This is a highly readable and well-organized desktop companion for practicing attorneys (i.e., prosecutors, litigators or inside counsel), patent agents, and students, who are seeking effortless entry into case law dealing with patents in modern biotechnology. The text, authored by firm director Jorge A. Goldstein, Ph.D., focuses on biotechnology cases decided by the Court of Appeals for the Federal Circuit, its predecessor, the Court of Customs and Patent Appeals, the U.S. Supreme Court, and the U.S. Patent and Trademark Office Appellate Boards.
The casebook highlights prominent biotech case-law and, for each case discussed, includes a summary of the holding, separate patent claims, technology drawings or other facts needed for a clearer understanding, and verbatim citations and quotes from the tribunal. Throughout the publication, Dr. Goldstein includes comments discussing trends in the case law, critiques of outlier cases, and attempts to provide unifying themes to the historical and thematic development of the law. Also included are summary diagrams that provide immediate understanding of a body of case law, such as, for example, the development of a drug from early research to a time after approval by the FDA.
"U.S. Biotechnology Patent Law distills my 40 years' experience pioneering the highly technical and specialized field of biotechnology patent law. It is my sincere hope that this text (and its planned updates) willhelp inspire and educate the lawyers and patent agents who will secure and litigate patents for the next generation of biotech breakthroughs," said Dr. Goldstein.
U.S. Biotechnology Patent Law is being published both in paper and online versions and is available for purchase online.
About the Author:
A pioneer in biotechnology patent law and founding partner of Sterne Kessler, Jorge
A. Goldstein, Ph.D., has almost forty years' experience in preparing, prosecuting, licensing, enforcing and litigating biotech patents before the U.S. and foreign patent offices and tribunals. Dr. Goldstein is also the founder of the firm's unique pro bono practice dedicated to integrating intellectual property law concepts with economic, social, and cultural rights, to empower disenfranchised and impoverished communities' economic and social development. Dr. Goldstein received his J.D. from The George Washington Universitywith high honors, his Ph.D. in Chemistry from Harvard, and his B.S. in Chemistry from Rensselaer Polytechnic Institute.
About Sterne Kessler:
Founded in 1978 and based in Washington, DC, Sterne Kessler is dedicated exclusively to the protection, transfer, and enforcement of intellectual property rights. Our team of attorneys, registered patent agents, students and technical specialists include some of the country's most respected practitioners of intellectual property law. Most of our professionals hold an advanced level degree, including more than 55 masters degrees and almost 55 with a doctorate in science or engineering -- credentials wide and deep enough to fill the faculty of a science-oriented university.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sterne-kessler-director-authors-us-biotechnology-patent-law-300342629.html
SOURCE Sterne, Kessler, Goldstein & Fox P.L.L.C.PR Newswire
Last updated on: 11/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.